Cargando…

Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations

Although clinical antitumor activity of Tumor Treating Fields (TTFields) has been reported in malignant pleural mesothelioma (MPM) patients, the mechanisms behind the different selectivity displayed by the various MPM histotypes to this physical therapy has not been elucidated yet. Taking advantage...

Descripción completa

Detalles Bibliográficos
Autores principales: Mannarino, Laura, Mirimao, Federica, Panini, Nicolò, Paracchini, Lara, Marchini, Sergio, Beltrame, Luca, Amodeo, Rosy, Grosso, Federica, Libener, Roberta, De Simone, Irene, Ceresoli, Giovanni L., Zucali, Paolo A., Lupi, Monica, D’Incalci, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287343/
https://www.ncbi.nlm.nih.gov/pubmed/35840560
http://dx.doi.org/10.1038/s41419-022-05073-4
_version_ 1784748232468856832
author Mannarino, Laura
Mirimao, Federica
Panini, Nicolò
Paracchini, Lara
Marchini, Sergio
Beltrame, Luca
Amodeo, Rosy
Grosso, Federica
Libener, Roberta
De Simone, Irene
Ceresoli, Giovanni L.
Zucali, Paolo A.
Lupi, Monica
D’Incalci, Maurizio
author_facet Mannarino, Laura
Mirimao, Federica
Panini, Nicolò
Paracchini, Lara
Marchini, Sergio
Beltrame, Luca
Amodeo, Rosy
Grosso, Federica
Libener, Roberta
De Simone, Irene
Ceresoli, Giovanni L.
Zucali, Paolo A.
Lupi, Monica
D’Incalci, Maurizio
author_sort Mannarino, Laura
collection PubMed
description Although clinical antitumor activity of Tumor Treating Fields (TTFields) has been reported in malignant pleural mesothelioma (MPM) patients, the mechanisms behind the different selectivity displayed by the various MPM histotypes to this physical therapy has not been elucidated yet. Taking advantage of the development of well characterized human MPM cell lines derived from pleural effusion and/or lavages of patients’ thoracic cavity, we investigated the biological effects of TTFields against these cells, representative of epithelioid, biphasic, and sarcomatoid histotypes. Growth inhibition and cell cycle perturbations caused by TTFields were investigated side by side with RNA-Seq analyses at different exposure times to identify pathways involved in cell response to treatment. We observed significant differences of response to TTFields among the cell lines. Cell cycle analysis revealed that the most sensitive cells (epithelioid CD473) were blocked in G(2)M phase followed by formation of polyploid cells. The least sensitive cells (sarcomatoid CD60) were only slightly affected by TTFields with a general delay in all cell cycle phases. Apoptosis was present in all samples, but while epithelioid cell death was already observed during the first 24 h of treatment, sarcomatoid cells needed longer times before they engaged apoptotic pathways. RNA-Seq experiments demonstrated that TTFields induced a transcriptional response already detectable at early time points (8 h). The number of differentially expressed genes was higher in CD473 than in CD60 cells, involving several pathways, such as those pertinent to cell cycle checkpoints, DNA repair, and histone modifications. Our data provide further support to the notion that the antitumor effects of TTFields are not simply related to a non-specific reaction to a physical stimulus, but are dependent on the biological background of the cells and the particular sensitivity to TTFields observed in epithelioid MPM cells is associated with a higher transcriptional activity than that observed in sarcomatoid models.
format Online
Article
Text
id pubmed-9287343
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-92873432022-07-17 Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations Mannarino, Laura Mirimao, Federica Panini, Nicolò Paracchini, Lara Marchini, Sergio Beltrame, Luca Amodeo, Rosy Grosso, Federica Libener, Roberta De Simone, Irene Ceresoli, Giovanni L. Zucali, Paolo A. Lupi, Monica D’Incalci, Maurizio Cell Death Dis Article Although clinical antitumor activity of Tumor Treating Fields (TTFields) has been reported in malignant pleural mesothelioma (MPM) patients, the mechanisms behind the different selectivity displayed by the various MPM histotypes to this physical therapy has not been elucidated yet. Taking advantage of the development of well characterized human MPM cell lines derived from pleural effusion and/or lavages of patients’ thoracic cavity, we investigated the biological effects of TTFields against these cells, representative of epithelioid, biphasic, and sarcomatoid histotypes. Growth inhibition and cell cycle perturbations caused by TTFields were investigated side by side with RNA-Seq analyses at different exposure times to identify pathways involved in cell response to treatment. We observed significant differences of response to TTFields among the cell lines. Cell cycle analysis revealed that the most sensitive cells (epithelioid CD473) were blocked in G(2)M phase followed by formation of polyploid cells. The least sensitive cells (sarcomatoid CD60) were only slightly affected by TTFields with a general delay in all cell cycle phases. Apoptosis was present in all samples, but while epithelioid cell death was already observed during the first 24 h of treatment, sarcomatoid cells needed longer times before they engaged apoptotic pathways. RNA-Seq experiments demonstrated that TTFields induced a transcriptional response already detectable at early time points (8 h). The number of differentially expressed genes was higher in CD473 than in CD60 cells, involving several pathways, such as those pertinent to cell cycle checkpoints, DNA repair, and histone modifications. Our data provide further support to the notion that the antitumor effects of TTFields are not simply related to a non-specific reaction to a physical stimulus, but are dependent on the biological background of the cells and the particular sensitivity to TTFields observed in epithelioid MPM cells is associated with a higher transcriptional activity than that observed in sarcomatoid models. Nature Publishing Group UK 2022-07-15 /pmc/articles/PMC9287343/ /pubmed/35840560 http://dx.doi.org/10.1038/s41419-022-05073-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Mannarino, Laura
Mirimao, Federica
Panini, Nicolò
Paracchini, Lara
Marchini, Sergio
Beltrame, Luca
Amodeo, Rosy
Grosso, Federica
Libener, Roberta
De Simone, Irene
Ceresoli, Giovanni L.
Zucali, Paolo A.
Lupi, Monica
D’Incalci, Maurizio
Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
title Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
title_full Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
title_fullStr Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
title_full_unstemmed Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
title_short Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
title_sort tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287343/
https://www.ncbi.nlm.nih.gov/pubmed/35840560
http://dx.doi.org/10.1038/s41419-022-05073-4
work_keys_str_mv AT mannarinolaura tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT mirimaofederica tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT panininicolo tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT paracchinilara tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT marchinisergio tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT beltrameluca tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT amodeorosy tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT grossofederica tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT libenerroberta tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT desimoneirene tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT ceresoligiovannil tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT zucalipaoloa tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT lupimonica tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations
AT dincalcimaurizio tumortreatingfieldsaffectmesotheliomacellproliferationbyexertinghistotypedependentcellcyclecheckpointactivationsandtranscriptionalmodulations